Thumbnail
Access Restriction
Open

Author Debono, M. ♦ Abbott, B. J. ♦ Fukuda, D. S. ♦ Barnhart, M. ♦ Willard, K. E. ♦ Molloy, R. M. ♦ Michel, K. H. ♦ Turner, J. R. ♦ Butler, T. F. ♦ Hunt, A. H.
Source J-STAGE
Content type Text
Publisher JAPAN ANTIBIOTICS RESEARCH ASSOCIATION
Language English
Abstract The antifungal antibiotic, echinocandin B (ECB), was modified by a sequential procedure in which the initial step involved enzymatic removal of the native N-linoleoyl group from the N-terminus using an Actinoplanes utahensis culture. The resulting product, ECB nucleus, was reacylated using active esters or acid halides of various substituted acids to give a series of ECB analogs. These analogs possessed anti-Candida activity both in vitro and in vivo (mice). Other studies have shown that one of these, cilofungin, the 4-n-octyloxybenzoyl-ECB analog (LY121019), has excellent anti-Candida activity, low toxicity and is superior to other available antifungal antibiotics.
ISSN 00218820
Learning Resource Type Article
Publisher Date 1989-03-25
e-ISSN 18811469
Journal The Journal of Antibiotics(antibiotics1968)
Volume Number 42
Issue Number 3
Page Count 9
Starting Page 389
Ending Page 397


Open content in new tab

   Open content in new tab